Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 14/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 6/20 | 0.34 |
| ▸ | F10 | P00742 | 6/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575988 | 0.86 | LMNA (0.49) | LMNAERN1 | |
| SCHEMBL1620761 | 0.82 | LMNA (0.40) | LMNAERN1 | |
| SCHEMBL3855768 | 0.75 | ERN1 (0.43) | LMNAERN1 | |
| SCHEMBL3849562 | 0.75 | LMNA (0.42) | LMNAERN1 | |
| SCHEMBL3463352 | 0.75 | LMNA (0.51) | LMNAERN1FFAR4 | |
| SCHEMBL3851238 | 0.72 | KMT2A (0.43) | F7 | |
| SCHEMBL3851241 | 0.72 | KMT2A (0.43) | F7 | |
| SCHEMBL5047674 | 0.71 | F10 (0.49) | F7F2F10PRSS1PRSS2 | |
| SCHEMBL6901917 | 0.71 | LMNA (0.50) | LMNAERN1 | |
| SCHEMBL10451669 | 0.71 | LMNA (0.58) | LMNAERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576098-B2 | Heterocyclic compounds as inhibitors of factor VIIa | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1828152-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | BRISTOL MYERS SQUIBB CO (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1828152-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | Bristol-Myers Squibb Company (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060211720-A1 | Heterocyclic compounds as inhibitors of factor VIIa | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| WO-2006062972-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211720-A1 | Heterocyclic compounds as inhibitors of factor VIIa | TFPI, F7, HABP2 | LMNA 729/4885F7 2/4885ERN1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.